Table of contents

VOLUME I – Diagnosis

• From the editors: Introducing the digital edition of The PCR-EAPCI Percutaneous Interventional Cardiovascular Medicine Textbook FREE ACCESS
• Foreword: A European touch FREE ACCESS
• Foreword: Why a textbook? Why this textbook? FREE ACCESS
• Preface: PCR-EAPCI Percutaneous Interventional Cardiovascular Medicine Textbook: a step and benchmark for a future model in education FREE ACCESS
• Introduction: Bringing it all together, the Genesis of the PCR EAPCI textbook FREE ACCESS

Part I – Foundations of interventional cardiovascular medicine

• 1.1 - A history of cardiac catheterisation
• 1.2 - A history of percutaneous coronary intervention
• 1.3 - Right and left heart catheterisation
• 1.4 - Vascular access 2 CME credit(s)
• 1.5 - Vascular closure
• 1.6 - Cardiac transseptal catheterisation
• 1.7 - Catheterisation for peripheral diagnostic and interventional procedures
• 1.8 - Cardiac catheterisation in children and adults with grown-up congenital heart disease
• 1.9 - Endomyocardial biopsy
• 1.10 - Pericardiocentesis
• 1.11 - Percutaneous ventricular assistance
• 1.12 - Radiation protection
• 1.13 - Contrast agents and renal protection
• 1.14 - Sedation, pain management and resuscitation
• 1.15 - Biostatistics for the interventionist

Part II – Diagnostic cardiovascular modalities and their application

• 2.1 - Cardiac biomarkers
• 2.2 - Fundamentals of coronary biomechanics
• 2.3 - Non-invasive imaging for coronary disease
• 2.4 - Non-invasive imaging for structural heart disease
• 2.5 - Imaging for peripheral artery disease
• 2.6 - Invasive diagnostic coronary angiography
• 2.7 - Invasive haemodynamic assessment
• 2.8 - Invasive physiological assessment of coronary disease 2 CME credit(s)
• 2.9 - Assessment of coronary vasoreactivity and the microcirculation
• 2.10 - Intracardiac echocardiography
• 2.11 - Intravascular ultrasound
• 2.12 - Optical coherence tomography
• 2.13 - Near-infrared spectroscopy

VOLUME II – Intervention I

Part III – Percutaneous interventions for cardiovascular disease

• 3.1 - Guide catheters and wires 2 CME credit(s)
• 3.2 - Balloon angioplasty technology
• 3.3 - Coronary artery stents
• 3.4 - Bioresorbable scaffolds FREE ACCESS
• 3.5 - Drug-coated balloons
• 3.6 - Rotational atherectomy
• 3.7 - Directional atherectomy
• 3.8 - Laser therapy
• 3.9 - Distal protection and thrombectomy
• 3.10 - Bifurcation lesions 2 CME credit(s)
• 3.11 - Ostial lesions
• 3.12 - Left main coronary artery disease FREE ACCESS
• 3.13 - Chronic total occlusions
• 3.14 - Saphenous vein graft disease
• 3.15 - Risk stratification and risk models in revascularisation
• 3.16 - Interventions for stable coronary disease
• 3.17 - Interventions for ST-segment elevation acute myocardial infarction
• 3.18 - Interventions for non-ST-segment elevation acute coronary syndromes
• 3.19 - Interventions for patients with diabetes mellitus
• 3.20 - Interventions for patients with chronic renal disease
• 3.21 - Secondary revascularisation
• 3.22 - Hybrid interventions
• 3.23 - Cardiogenic shock 2 CME credit(s)
• 3.24 - The prevention and management of complications during percutaneous coronary intervention FREE ACCESS
• 3.25 - Stent thrombosis
• 3.26 - In-stent restenosis
• 3.27 - Peri-procedural and post-procedural antithrombotic pharmacotherapy 2 CME credit(s)
• 3.28 - Secondary prevention and follow-up

VOLUME III – Intervention II

Part III – Percutaneous interventions for cardiovascular disease

• 3.29 - Percutaneous interventions in mitral and tricuspid stenosis and in failure of mitral and tricuspid bioprostheses
• 3.30 - Percutaneous mitral valve repair
• 3.31 - Balloon aortic valvuloplasty
• 3.32 - Transcatheter aortic valve implantation 3 CME credit(s)
• 3.33 - Percutaneous pulmonary valvuloplasty
• 3.34 - Percutaneous pulmonary valve implantation
• 3.35 - Atrial septal defect and patent foramen ovale closure
• 3.36 - Ventricular septal defect closure
• 3.37 - Patent ductus arteriosus closure
• 3.38 - Left atrial appendage occlusion
• 3.39 - Coarctation of the aorta
• 3.40 - Interventions for congenital and acquired pulmonary vein stenosis
• 3.41 - Percutaneous closure of paravalvular leaks
• 3.42 - Carotid artery stenting
• 3.43 - Subclavian, brachiocephalic and vertebral interventions
• 3.44 - Thoracic and abdominal aortic disease
• 3.45 - Interventions in the reno-visceral circulation
• 3.46 - Peripheral arterial occlusive disease 2 CME credit(s)
• 3.47 - Interventions for varicose veins
• 3.48 - Closure of arteriovenous fistulae and malformations
• 3.49 - Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
• 3.50 - Alternative techniques to alcohol septal ablation for hypertrophic obstructive cardiomyopathy
• 3.51 - Renal sympathetic denervation FREE ACCESS
• 3.52 - Techniques of myocardial stem cell delivery
• 3.53 - Cell-based regenerative therapy
• 3.54 - Pulmonary embolism and pulmonary hypertension

VOLUME IV – Perspective

Part IV – Interventional cardiovascular medicine into context

• 4.1 - The Heart team 1 CME credit(s)
• 4.2 - Patient information, ethics, and informed consent
• 4.3 - The cardiac catheterisation laboratory environment
• 4.4 - Administration and data collection
• 4.5 - Registry studies and post-marketing surveillance
• 4.6 - Clinical trial design
• 4.7 - Quality of life assessment
• 4.8 - Risk-benefit analysis
• 4.9 - Cost and cost-effectiveness
• 4.10 - Interventional cardiology training
• 4.11 - Consensus on definitions of clinical endpoints : percutaneous coronary and valvular intervention trials 2 CME credit(s)
• 4.12 - Consensus on definitions of clinical endpoints : carotid artery and supra-aortic trunk revascularisation trials

Part V – Annexes

• 5.1 - Interventional pharmacology
• 5.2 - Interventional innovation landscape
• 5.3 - ARC definitions of clinical endpoints for interventional trials
• 5.4 - Cardiology audit and registration data standards
• 5.5 - Abridged ESC guidelines for interventional practice
• 5.6 - The global burden of cardiovascular disease